Abstract 378O
Background
Recent studies showed the positive impact of supportive care programs on patients. Possible benefits include the prevention of incorrect medication intake, a decrease of treatment-related symptoms and the reduction of hospitalization due to adverse events. MOATT is a standardized patient coaching program which might be suitable to improve the therapy management of BC patients with oral treatments. Aim of this study was to investigate the impact of MOATT on persistence and therapy management under ABA+ET.
Methods
IMPACT (NCT04030728) was a prospective randomized, controlled trial in patients with hormone receptor positive, HER2-negative aBC treated with ABA+ET. Patients were randomized to LC vs. MOATT. Primary endpoint was the persistence rate after 24 weeks of treatment. Further endpoints included compliance rate, the number of dose reduction and dose interruptions.
Results
A total of 211 patients were randomized between 06/20 and 02/22. Persistence probability after 24 weeks was 0.71 (95%CI 0.63-0.81) with LC and 0.82 (95%CI: 0.74-0.90) with MOATT (hazard ratio: 0.59 (95%CI: 0.32-1.07; plog-rank = 0.078). Disease progression or death were the main reasons for therapy discontinuation in 14 cases in the LC arm and in 10 cases in the MOATT arm. A decision for a permanent discontinuation of ABA in the first 24 weeks was seen in 14 patients (14.1%) in the LC arm and 8 Patients (7.8%) in the MOATT arm. Dose reductions were planned in 24.5% of patients with LC and in 17.2% of patients in the MOATT arm. Therapy interruptions were planned in 14.9% of LC-patients and 10.1% in the MOATT arm.
Conclusions
The risk of therapy discontinuation within the first 24 weeks of treatment is clinically relevant. Coaching with MOATT reduced the probability for permanent therapy discontinuations by about 40% during the first 6 months of therapy. Standardized patient coaching improved therapy management of oral cancer therapies like abemaciclib. Patient coaching might be very useful to improve therapy management also in the adjuvant breast cancer setting.
Clinical trial identification
NCT04030728 and July 24, 2019.
Editorial acknowledgement
Legal entity responsible for the study
Onco Medical Consult GmbH, Tennelbachstr. 59, D-65193 Wiesbaden.
Funding
Lilly.
Disclosure
P. Fasching: Financial Interests, Personal, Advisory Board: Roche, Novartis, Pfizer, Daiichi Sankyo, Eisai, Merck, Sharp & Dohme, AstraZeneca, Hexal, Lilly, Pierre Fabre, Seagen, Agendia, Sanofi Aventis; Financial Interests, Personal, Invited Speaker: Novartis, Daiichi Sankyo, Eisai, Merck, Sharp & Dohme, AstraZeneca, Lilly, Seagen, Gilead; Financial Interests, Personal, Other, Medical Writing Support: Roche; Financial Interests, Institutional, Local PI: BionTech, Cepheid; Non-Financial Interests, Member: ASCO, Arbeitsgemeinschaft für Gynäkologische Onkologie e.V., Translational Research in Oncology, Deutsche Gesellschaft für Senologie e.v.. L. Mueller: Financial Interests, Institutional, Invited Speaker: Iomedico. E. Belleville: Financial Interests, Institutional, Other, Research Support/Medical Education Support: Novartis, Lilly, MSD; Financial Interests, Personal, Other, Clinical Research Management/Medical Education: ClinSol; Financial Interests, Institutional, Other, Medical Education Support: Gilead, Daiichi Sankyo, Pfizer, Astra Zenca, Hexal, Sandoz, Roche, Amgen, Ipsen, Eisai, SUN Pharma, Sanofi, Immunocore, Takeda, BMC, SERVIER, Janssen, Stemline; Financial Interests, Institutional, Other, Clinical Research Support / Medical Education Support: Seagen; Financial Interests, Personal, Officer: Onkowissen, Clinsol, High5md; Financial Interests, Institutional, Funding, Research Support: Lilly, Novartis, Seagen, Bayer, Pfizer, Daiichi. L. Rieger: Financial Interests, Personal, Stocks/Shares: Pfizer. H. Tesch: Financial Interests, Personal, Advisory Board: AstraZeneca, Daiichi, Exact Science, Gilead, GSK, Lilly, MSD, Myan, Novartis, Pfizer, Piere Fabre, Roche Pharma GmbH, Seagan; Financial Interests, Personal, Other, Reporting SABSC, ESMO 2022 : ClinSol; Financial Interests, Personal, Other, Travel Expenses: GSK, Pfizer; Financial Interests, Personal, Writing Engagement: Novartis; Financial Interests, Personal, Other, Clinical trial manager: Novartis; Financial Interests, Personal, Invited Speaker, SABCS 2020 : Onkowissen; Financial Interests, Personal, Other, ownership of shares: CHOP GmbH, Onco Medical Consul, VISION MED GmbH, Care and Coach GmbH; Financial Interests, Personal, Other, Medical Co-Lead Impact: Lilly; Non-Financial Interests, Member: ASCO. All other authors have declared no conflicts of interest.
Resources from the same session
381O - First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors
Presenter: Jian Zhang
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
376O - Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
Presenter: Shanu Modi
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 381O and 376O
Presenter: Giampaolo Bianchini
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Webcast
377O - A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03
Presenter: Sara Hurvitz
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 377O and 378O
Presenter: Janice Wing-Hang Tsang
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Webcast